

PROTECTIVE ORDER MATERIAL

Paper No. ____
Filed: July 29, 2015

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

COALITION FOR AFFORDABLE DRUGS VI LLC
Petitioner,

v.

CELGENE CORPORATION
Patent Owner

Case IPR2015-01102
Patent 6,315,720

**PATENT OWNER PRELIMINARY RESPONSE
PURSUANT TO 35 U.S.C. § 313 AND 37 C.F.R. § 42.107**

PROTECTIVE ORDER MATERIAL

Patent Owner Preliminary Response

IPR2015-01102
Patent 6,315,720

TABLE OF CONTENTS

	<u>Page</u>
I. INTRODUCTION	1
II. BACKGROUND	3
A. The Challenge of Protecting A Fetus From A Teratogenic Drug While Allowing A Patient Access to Its Efficacy.....	5
B. Previous Attempts to Control Access to Other Drugs Were Unsuccessful	11
C. The '720 Patent	13
III. ARGUMENT.....	19
A. The Petition Should Be Denied Because CFAD Has Failed To Show A Reasonable Likelihood That The Claims Are Obvious	19
1. CFAD’s Expert Declaration Is Entitled To “little or no weight”	19
(a) Dr. Fudin Is Not A POSA.....	20
(b) Dr. Fudin’s Opinions Are Unsupported, Verbatim Recitations of CFAD’s Conclusory Arguments	21
2. The Petition Fails To Address The Redundancy With The 1096 And 1103 Petitions.....	22
3. Ground 1: The Claimed Inventions Would Not Have Been Obvious Over Powell, Dishman, and Cunningham	24
(a) CFAD Fails To Address Both the Claims and the Prior Art “As a Whole”	24
(b) CFAD Has Not Provided A Motivation To Combine Powell With Dishman or Cunningham.....	25

PROTECTIVE ORDER MATERIAL

Patent Owner Preliminary Response

IPR2015-01102
Patent 6,315,720

- (c) The Ground 1 References Fail To Disclose, Teach, or Suggest Key Elements of the Claimed Inventions31
 - i. Claim 1 Is Not Rendered Obvious By Powell, Cunningham, And Dishman.....32
 - 1) Element 1(c).....32
 - 2) Element 1(d).....34
 - 3) Element 1(e).....35
 - ii. Dependent Claims 2-27 Would Not Have Been Obvious Over Powell In View Of Dishman And In Further View Of The Knowledge Of a POSA37
 - 1) Claim 538
 - 2) Claim 639
 - 3) Claim 940
 - 4) Claim 1041
 - 5) Claims 13, 14, 23-2541
 - 6) Claims 16 and 1743
 - 7) Claims 18 and 1944
 - iii. Independent Claim 28 And Dependent Claims 29-32 Would Not Have Been Obvious Over Powell In View Of Dishman In Further View Of Cunningham And The Knowledge Of a POSA46
 - 1) Claim 2846
 - 2) Claims 29-3247
- 4. CFAD Fails To Address The Objective Evidence of Nonobviousness Regarding the '720 Patent48

PROTECTIVE ORDER MATERIAL

Patent Owner Preliminary Response

IPR2015-01102
Patent 6,315,720

- (a) Long-felt Need Further Supports The
Nonobviousness Of The Claimed Inventions.....49
- (b) Commercial Success Further Supports The
Nonobviousness Of The Claimed Inventions.....51
- (c) Third-Party Praise And Awards Further Supports
The Nonobviousness Of The Claimed Inventions52
- (d) Licensing by Others Further Supports The
Nonobviousness Of The Claimed Inventions.....52
- (e) Unexpected Results Further Supports The
Nonobviousness Of The Claimed Inventions.....52
- B. The Petition Should Be Denied
Under 35 U.S.C. §§ 314(a) and 316(b)54
- C. The Petition Should Be Denied
For Failing To Name All Real Parties-In-Interest57
- IV. CONCLUSION.....59

PROTECTIVE ORDER MATERIAL

Patent Owner Preliminary Response

IPR2015-01102
Patent 6,315,720

I. INTRODUCTION

Pursuant to 35 U.S.C. § 313 and 37 C.F.R. § 42.107(a), Patent Owner Celgene Corporation (“Celgene”) submits this Preliminary Response to Coalition For Affordable Drugs VI LLC’s (“CFAD”) Petition for *Inter Partes* Review (the “Petition”) of U.S. Patent No. 6,315,720 (the “’720 patent”).

The ’720 patent describes and claims improved methods for delivering a potentially dangerous drug to a patient (including teratogenic drugs such as thalidomide) while avoiding the occurrence of adverse side effects (such as birth defects of the type associated with thalidomide). The inventions were conceived as part of Celgene’s efforts to significantly improve its existing program for controlling patient access to thalidomide, which was known as the System for Thalidomide Education and Prescribing Safety, or S.T.E.P.S.[®] The improved program, which Celgene called Enhanced S.T.E.P.S.[®], is an embodiment of the ’720 patent and has been used in connection with thalidomide and other potentially teratogenic pharmaceutical products since 2001. During that time it has successfully prevented 100% of drug-related birth defects. In fact, the inventions of the ’720 patent were so successful and innovative that the FDA required other drug manufacturers to copy Celgene’s patented methods if they wanted to keep their products on the market, resulting in licenses to several of Celgene’s patents, including the ’720 patent.

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.